Body1.com: Great Information, Real Community, Better Living.
 Register
 Login
 Main Page
 Education Center
Conditions
Diagnostics
Procedures
Find a Physician
First Aid
Online Resources
Dr. Lyle J. Micheli  Health Care
 Hero™

Dr. Lyle J. Micheli:
Orthopedic Care for Young Athletes.
About Heroes
 Join the Discussion in  Our Forums
 Health Community
Forums
Health Blogs
 Health News
Health Feature
Latest Health News
Life Stories
Health Calendar
 Video Library
 International
 Content Syndication
advertisement
Search the Body1 Network
September 02, 2010  
HEALTH NEWS: Health Feature

  • Printer Friendly Version
  • Email this Article
  • Links/Reprints
  • MedImmune Recalls 4.7 million Doses of Nasal H1N1

    MedImmune Recalls 4.7 million Doses of Nasal H1N1 Vaccine


    December 24, 2009

     

    AstraZeneca’s MedImmune unit to voluntarily recall 4.7 million doses of its nasal H1N1 flu vaccine citing a loss of effectiveness, the U.S. Food and Drug Administration reported Wednesday.

    Only 3,000 of those units were in warehouses, however, as the remainder had been administered when the drug was still at full potency. Those who already received the vaccine do not need to be vaccinated again as the drug was effective at the time of use. The company has recommended that all remaining units marked with expirations dates between Jan. 19 and Jan. 26, 2010, not be administered. All vaccine-producing companies check their drugs for effectiveness at regular intervals.

    “The doses were well within potency specifications at the time of distribution,” Tor Constantino, an AstraZeneca spokesman, told Reuters.

    On Dec. 15, Sanofi-Aventis recalled 800,000 units of its pediatric H1N1 vaccine for similar reasons. Antigen, the virus component in the vaccine, had atrophied to an extent that made the vaccine less effective.

    Reuters also reported that the MedImmune recall was not for safety issues, but to inform health-care providers who have some of the vaccine left over not to administer it. Using the drug would bear no ill effects on the patient, but would not adequately immunize them from the virus.

    Dr. Anne Schuchat told Reuters on Tuesday that 111 million doses of H1N1 vaccine have been made available through this point in the flu season.

    The U.S. Health and Human Services department contracted five companies – Sanofi Aventis, CSL of Australia, AstraZeneca unit MedImmune and GlaxoSmithKline – to produce a combined 251 million doses of the vaccine.

    According to Schuchat, H1N1 infections have decreased throughout the country; however it is still the most widespread strain of flu circulating today.

    While concern over the disease has deflated, Schuchat reiterated that it’s crucial that the nation does not forget about the threat as there is no way to eliminate possible resurgence.

    “Coverage was about twice as high in children as it was in adults,” she said. “That’s really good news because usually with seasonal flu there’s a lot more vaccination of adults, including seniors, than children. But with the H1N1 vaccine we were targeting children because they have been so hard hit by the virus.”

    Earlier in the flu season, reports circled of the lack of H1N1 vaccine. Schuchat said, however, that despite Wednesday’s recall, the vaccine supply is plentiful and now is a good time for those not yet vaccinated to do so.



    Discuss Swine Flu in our Forums

    Last updated: 24-Dec-09

    Comments

  • Add Comment
  •    
    Interact on Body1

    Discuss this topic with others.
     
    Feature Archives
    Health Feature Archives

    Pursuing Human Limb Regeneration

    Doctors warn that using domestic spoons to give children medicine increases overdose risk

    U.S. Army Dogs Help Battle PTSD

    Incidence of malaria jumps when Amazon forests are cut

    Europe's First Mind Controlled Arm Gives New Lease Of Life To Patient

    Next 5 Features ...

    More Features...

     
     
    Related Content
    US Senate Healthcare Bill to Place Tax on Cosmetic Surgery

    Knee Replacement in Elderly Patients Shown to Improve Balance

    Heart Failure

    Berns Triplets Back on The Today Show - An update on their treatments

    Qualitest Pharmaceuticals Issues a Voluntary Nationwide Recall of All Accusure® Insulin Syringes

    More Features ...
     
    Home About Us Press Jobs Advertise With Us Contact Us
    advertisement
    ©1999- 2010 Body1, Inc. All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.